Horizon Therapeutics

KRYSTEXXA

Manufacturer:

Horizon Therapeutics

Krystexxa HCPCS:

J2507

HCPCS Code Descriptor:

Injection, pegloticase, 1 mg

Category:

J Code

Krystexxa NDCs:

75987-0080-10

Primary Type:

Immunology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

75987-0080-10

About Krystexxa:

KRYSTEXXA is an Immunology drug manufactured by Horizon Therapeutics and administered via the Intravenous route of administration. The J Code: J2507 is aligned to the drug KRYSTEXXA.

ACCESS PRICING AND MORE BY REGISTERING

J2507 Added Date:

January 1, 2012

J2507 Effective Date:

January 1, 2012

J2507 Termination Date:

HCPCS Active

Krystexxa billing and coding information can be found through Horizon Therapeutics at the link below:
Krystexxa patient assistance information can be found through Amgen at the URL: https://www.krystexxahcp.com/rheumatology/
KRYSTEXXA prescribing information can be found at the link below:
Information regarding KRYSTEXXA’s side effects can be found at MedlinePlus